EA201792470A1 - Способы улучшения адсорбции полисахарид-белковых конъюгатов и полученная из них композиция поливалентной вакцины - Google Patents

Способы улучшения адсорбции полисахарид-белковых конъюгатов и полученная из них композиция поливалентной вакцины

Info

Publication number
EA201792470A1
EA201792470A1 EA201792470A EA201792470A EA201792470A1 EA 201792470 A1 EA201792470 A1 EA 201792470A1 EA 201792470 A EA201792470 A EA 201792470A EA 201792470 A EA201792470 A EA 201792470A EA 201792470 A1 EA201792470 A1 EA 201792470A1
Authority
EA
Eurasian Patent Office
Prior art keywords
adsorption
polysaccharide
compound
improve
methods
Prior art date
Application number
EA201792470A
Other languages
English (en)
Inventor
Раджив Мхаласакант Шере
Хитеш Кумар Малвийя
Суопан Кумар Джана
Самбхаджи Шанкар Писал
Аша Дайнеш Маллия
Сунил Махор
Маниш Махешкумар Гаутам
Читан Вилас Джоши
Венката Вамси Кришна Малепати
Прашант Шиваджи Джашав
Original Assignee
Серум Инститьют Оф Индия Прайват Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Серум Инститьют Оф Индия Прайват Лтд. filed Critical Серум Инститьют Оф Индия Прайват Лтд.
Publication of EA201792470A1 publication Critical patent/EA201792470A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение предлагает способы для приготовления устойчивых композиций поливалентной противопневмококковой полисахарид-белковой конъюгированной вакцины. Настоящие устойчивые композиции показывают оптимальную процентную адсорбцию для каждого конъюгата, где агрегация может быть предотвращена за счет применения: i) индивидуальной или отдельной адсорбции для конъюгатов, которые в ином случае показывают меньшую процентную адсорбцию при комбинированной адсорбции; ii) буферной системы гистидин-янтарная кислота вместе со смещением pH от нейтрального pH к кислотному pH; iii) соотношения полисахарида и белка от 0,5 до 1,4; iv) использования шестилопаточной турбинной мешалки Раштона в сосуде композиции.
EA201792470A 2015-06-08 2016-06-03 Способы улучшения адсорбции полисахарид-белковых конъюгатов и полученная из них композиция поливалентной вакцины EA201792470A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2185MU2015 2015-06-08
PCT/IB2016/053265 WO2016199003A1 (en) 2015-06-08 2016-06-03 Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof

Publications (1)

Publication Number Publication Date
EA201792470A1 true EA201792470A1 (ru) 2018-10-31

Family

ID=57503115

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792470A EA201792470A1 (ru) 2015-06-08 2016-06-03 Способы улучшения адсорбции полисахарид-белковых конъюгатов и полученная из них композиция поливалентной вакцины

Country Status (18)

Country Link
US (1) US10729780B2 (ru)
EP (1) EP3302542A4 (ru)
JP (2) JP7258463B2 (ru)
KR (1) KR20240007690A (ru)
CN (1) CN107847571A (ru)
AU (1) AU2016276269B2 (ru)
BR (1) BR112017026343A2 (ru)
CA (1) CA2988366C (ru)
CO (1) CO2017012628A2 (ru)
EA (1) EA201792470A1 (ru)
IL (1) IL256118B (ru)
MX (1) MX2017015985A (ru)
MY (1) MY187461A (ru)
PE (1) PE20180460A1 (ru)
PH (1) PH12017502244A1 (ru)
SA (1) SA517390495B1 (ru)
WO (1) WO2016199003A1 (ru)
ZA (1) ZA201708325B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2692923C2 (ru) 2015-05-04 2019-06-28 Пфайзер Инк. Конъюгаты полисахарида стрептококка группы В и белка, способы получения конъюгатов, иммуногенные композиции, содержащие конъюгаты, и их применения
WO2016199003A1 (en) * 2015-06-08 2016-12-15 Serum Institute Of India Private Ltd. Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof
CN106822884B (zh) * 2016-12-28 2021-04-30 北京民海生物科技有限公司 一种多价肺炎球菌荚膜多糖结合疫苗的制备方法
CA3048981A1 (en) 2016-12-30 2018-07-05 Sutrovax, Inc. Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
EP3585803A4 (en) * 2017-02-24 2020-11-11 Merck Sharp & Dohme Corp. PNEUMOCOCCIC CONJUGATE VACCINE FORMULATIONS
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
WO2019050814A1 (en) * 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER
JP7369123B2 (ja) 2017-12-06 2023-10-25 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎球菌多糖類－タンパク質コンジュゲートを含む組成物およびその使用方法
CN108524926B (zh) * 2018-06-29 2021-06-29 康希诺生物股份公司 一种多价肺炎球菌结合疫苗的制剂组合及其应用
AU2019401535B2 (en) 2018-12-19 2023-12-14 Merck Sharp & Dohme Llc Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
JP2022535063A (ja) * 2019-06-05 2022-08-04 メルク・シャープ・アンド・ドーム・コーポレーション 免疫原性血清型３５ｂ肺炎球菌多糖類－タンパク質コンジュゲート及びそれを作成するためのコンジュゲーションプロセス
US20210070890A1 (en) 2019-09-06 2021-03-11 Serum Institute Of India Private Limited Method for obtaining purified bacterial polysaccharides
CN113607939A (zh) * 2021-08-05 2021-11-05 艾美探索者生命科学研发有限公司 肺炎球菌多糖结合疫苗各型结合原液吸附率测定方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
CN102302776B (zh) * 2003-01-30 2014-06-18 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
CA2534870C (en) * 2003-08-06 2014-05-06 Che-Hung Robert Lee Polysaccharide-protein conjugate vaccines
RU2442825C2 (ru) * 2005-04-18 2012-02-20 Новартис Вэксинес Энд Дайэгностикс Инк. Иммуногенные композиции, способы получения таких композиций и плазмида, включенная в такие композиции
MY150719A (en) * 2005-12-22 2014-02-28 Glaxosmithkline Biolog Sa Pneumococcal polysaccharide conjugate vaccine
WO2007071786A2 (en) * 2005-12-23 2007-06-28 Glaxosmithkline Biologicals Sa Conjugate vaccines
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US9610340B2 (en) * 2007-06-26 2017-04-04 Glaxosmithkline Biologicals, S.A. Vaccine comprising Streptococcus pneumoniae capsular polysaccharide conjugates
TW201136603A (en) 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
CA2819366A1 (en) * 2010-12-10 2012-06-14 Merck Sharp & Dohme Corp. Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions
HUE040914T4 (hu) 2012-01-30 2019-05-28 Serum Institute Of India Pvt Ltd Immunogén készítmény
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
CN104661684B (zh) * 2012-08-16 2018-03-20 辉瑞公司 糖缀合方法和组合物
CN103893751B (zh) * 2014-03-26 2016-04-20 天津康希诺生物技术有限公司 一种肺炎球菌多糖蛋白缀合疫苗及其制备方法
WO2016199003A1 (en) * 2015-06-08 2016-12-15 Serum Institute Of India Private Ltd. Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof

Also Published As

Publication number Publication date
ZA201708325B (en) 2019-05-29
NZ738090A (en) 2023-09-29
PH12017502244A1 (en) 2018-06-11
EP3302542A1 (en) 2018-04-11
MX2017015985A (es) 2018-08-15
AU2016276269A1 (en) 2018-01-18
CA2988366A1 (en) 2016-12-15
KR20180030498A (ko) 2018-03-23
BR112017026343A2 (pt) 2019-11-19
SA517390495B1 (ar) 2023-03-23
IL256118B (en) 2021-12-01
KR20240007690A (ko) 2024-01-16
EP3302542A4 (en) 2019-04-10
JP2018516962A (ja) 2018-06-28
US20180161445A1 (en) 2018-06-14
US10729780B2 (en) 2020-08-04
CN107847571A (zh) 2018-03-27
WO2016199003A1 (en) 2016-12-15
CA2988366C (en) 2021-12-07
PE20180460A1 (es) 2018-03-06
JP2021185152A (ja) 2021-12-09
CO2017012628A2 (es) 2018-03-28
IL256118A (en) 2018-02-28
JP7258463B2 (ja) 2023-04-17
MY187461A (en) 2021-09-23
AU2016276269B2 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
EA201792470A1 (ru) Способы улучшения адсорбции полисахарид-белковых конъюгатов и полученная из них композиция поливалентной вакцины
EA201690652A1 (ru) Высокобелковая композиция денатурированного сывороточного белка, связанные с ней продукты, способ их получения и применения
EA201790989A1 (ru) Стабильный препарат раствора белка, содержащего анти-vegf антитело в высокой концентрации
EA201590518A1 (ru) Стабильные водные составы адалимумаба
BR112018068278A2 (pt) derivado de 3-desóxi e suas composições farmacêuticas
EA201390472A1 (ru) Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
WO2014141152A3 (en) Low concentration antibody formulations
EA201400483A1 (ru) Составы собирателей и способы их применения
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201592055A1 (ru) 11-гидроксилпроизводные желчных кислот и их аминокислотные конъюгаты в качестве модуляторов фарнезоидных х-рецепторов
EA201590705A1 (ru) ПОЛУЧЕНИЕ РЕКОМБИНАНТНОЙ ВАКЦИНЫ В E.coli ПОСРЕДСТВОМ ЭНЗИМАТИЧЕСКОЙ КОНЪЮГАЦИИ
PH12017501473A1 (en) Novel proteins specific for pyoverdine and pyochelin
IN2015DN03322A (ru)
PE20141151A1 (es) Proteinas de union al antigeno cd27l
HRP20201242T1 (hr) Tekući farmaceutski pripravak
EA201692397A1 (ru) СТАБИЛИЗАЦИЯ ИММУНОГЛОБУЛИНОВ С ПОМОЩЬЮ ВОДНОГО СОСТАВА С ГИСТИДИНОМ ПРИ pH ОТ СЛАБОКИСЛОГО ДО НЕЙТРАЛЬНОГО
EA201590887A1 (ru) Композиция
EA201692279A1 (ru) Способ уменьшения иммуногенности белка и пептида
BR112014029174A2 (pt) composição de ativador geopolimérico, composição geopolimérica e método para a preparação de uma composição geopolimérica
PE20141706A1 (es) Anticuerpos de union a trombina y usos del mismo
BR112012029280A2 (pt) variante de domínio variável único de imunoglobulina antialbumina sérica, imunoglobulina anti-sa, ligando multiespecífico, proteína de fusão, composição, ácido nucleico, vetor, célula hospedeira isolada, e, uso de uma variante, ligando multiespecífico ou proteína de fusão
MX2012008439A (es) Gel oleoso.
BR112016020181A8 (pt) composições de ácido lipoico éster colina e métodos de uso.
HRP20191053T1 (hr) Nova stabilna formulacija
WO2015038689A3 (en) Cationic antiseptic compositions